A drug used to treat cholangiocarcinoma (a type of bile duct cancer) that is locally advanced and cannot be removed by surgery or has spread to other parts of the body. It is used in adults whose cancer has already been treated and has a FGFR2 gene fusion or other mutation in the FGFR2 gene. It is also being studied in the treatment of other types of cancer. Pemigatinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Pemazyre.